Protecting Families from Fertility Fraud Act of 2026
Summary
HR8295, the Protecting Families from Fertility Fraud Act of 2026, is a crime and law enforcement bill at the early referral stage in the House Judiciary Committee. It has no authorized funding and no direct market impact on publicly traded companies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8295 is a procedural crime bill with no market impact.
- 2.No funding or procurement is authorized.
- 3.No publicly traded companies are affected.
Market Implications
No market implications. The bill does not affect any publicly traded company's revenue, costs, or competitive position.
Full Analysis
-
What happened and its current status: On April 15, 2026, Representative Stephanie I. Bice (R-OK-5) introduced HR8295, the Protecting Families from Fertility Fraud Act of 2026, in the 119th Congress. The bill was referred to the House Committee on the Judiciary on the same day. It has 14 cosponsors and is categorized under the Crime and Law Enforcement policy area. The bill is in an early legislative stage with no further action beyond referral.
-
The money trail: This bill does not authorize or appropriate any specific funding amount. As a crime and law enforcement policy bill, it focuses on establishing legal standards or penalties related to fertility fraud, not on direct government spending or procurement. No funding mechanism is specified.
-
Structural winners and losers: The bill's subject matter—fertility fraud—relates to medical ethics and reproductive health practices, not to commercial products or services traded on public markets. No publicly traded companies are directly named or affected by the bill's provisions. The healthcare sector is broadly referenced, but the bill does not create revenue streams, mandates, or incentives for any specific company.
-
Real market data: No real market data was provided for analysis. The competitive landscape for fertility services involves private clinics and medical practices, not publicly traded entities.
-
Timeline: The bill has only three actions, all on April 15, 2026: introduction in the House and referral to the Judiciary Committee. No further hearings, markups, or votes are scheduled. Passage through the full House and Senate would require additional legislative steps.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.